Exendins and exendin agonists modified with albumin
AssigneeAmylin Pharmaceuticals, Inc.
InventorsKathryn S. Prickett, Andrew A. Young
Life of this patent
Estimating the term…
Abstract
Modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
Claims12
An agonist exendin-4 peptide analog linked to one albumin through the N-terminal or C-terminal amino acid of said agonist exendin-4 peptide analog.
An agonist exendin-4 peptide analog linked to one albumin through the N-terminal or C-terminal amino acid of said agonist exendin-4 peptide analog, wherein the agonist exendin-4 peptide analog comprises the amino acid sequence of:
- His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly(SEQ ID NO:
- 3).
Dependencies are inferred from the claim text.